簡易檢索 / 詳目顯示

回結果列表
研究生： 胡宸語
Hu, Chen-Yu
論文名稱： 尋找與肌萎縮性側索硬化症相關的過去病史：全人口病例對照研究
Finding diseases associated with amyotrophic lateral sclerosis: A total population-based case-control study
指導教授： 李子奇
Lee, Tzu-Chi
學位類別： 碩士
Master
系所名稱： 健康促進與衛生教育學系
Department of Health Promotion and Health Education
論文出版年： 2018
畢業學年度： 106
語文別： 英文
論文頁數： 95
中文關鍵詞： 肌萎縮性側索硬化症 、全民健保資料庫 、重大傷病資料庫 、疾病危險因子 、病例對照研究 、縱貫性研究
英文關鍵詞： amyotrophic lateral sclerosis, National Health Insurance Research Database, Serious Disabling Disease Database, risk disease, case–control study, cohort study
DOI URL： http://doi.org/10.6345/THE.NTNU.DHPHE.004.2018.F02
論文種類： 學術論文
相關次數： 點閱：253  下載：26 
分享至:
查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報

    • 研究重要性：
    在過去二十多年，許多研究發現與肌萎縮性側索硬化症（amyotrophic lateral sclerosis, ALS）有相關之疾病危險因子，但是卻少有研究將這些疾病在ALS發病之前的罹患時間納入討論。
    研究目標：
    探討ALS診斷日之前的疾病罹患情況來揭示與ALS有關之過去病史。
    研究設計：
    本研究為全人口病例對照研究。研究起始點為第一次ALS診斷日。
    研究資料：
    本研究使用全民健保資料庫（National Health Insurance Database, NHID）以及重大傷病資料庫（Serious Disabling Disease Database, SDD）。
    研究對象：
    從2007年1月1日至2013年12月31日止，共有705位15歲以上之ALS新發病例。將這些ALS病例以性別、年齡、居住地、以及投保薪資進行配對，配對比為1:20，得到14,100位對照組。
    研究暴露：
    篩選出ALS診斷日1 年前、3年前、5年前、7年前，以及9年前之過去病史，藉以評估該疾病發生是否為ALS的獨立變項。我們排除在首次診斷出ALS之前的1、1~2、1~4、1~6、1~8年間的疾病紀錄；疾病定義採用國際疾病分類碼第九版（International Classification of Diseases, 9th revision, ICD-9）的前三位數。
    主要結果測量：
    利用台灣衛生福利部之重大傷病資料庫（SDD）中的疾病紀錄，ALS 的ICD-9病例編碼為335.20。
    統計分析：
    以卡方檢定或T檢定檢查ALS新發病例與對照組間的人口學特徵之差異。首先使用單變數條件邏輯式廻歸模型篩選出過去病史，再藉由偽發現率（false discovery rate, FDR）調整p值，避免膨脹偽陽性。以偽發現率（FDR）調整後的p值<0.10作為相關疾病的初步篩選依據。除了經由單變數分析篩選疾病外，另外也進行多變數分析來評估先前疾病與ALS罹患風險之間的關聯。之後使用路徑分析（Path Analysis）來分析ALS病例及過去病史的關係網絡並討論之疾病間的影響力。
    結果：
    因配對研究設計的緣故，ALS患者平均年齡56.65 ± 11.38歲（平均值±標準差）與對照組相同；在705例ALS患者中，男性400例，女性305例（男女比為1.3：1）；50例患者住在鄉村，近一半的ALS病例為接受社會福利補助或家庭的依附投保成員。
    本研究多變數分析結果共篩選出28項過去病史與ALS有顯著相關，其中正相關疾病有17項，負相關疾病有11項。一般檢查（ICD-9:V70，OR=1.3，九年以前），耳朵疾病（ICD-9:388，OR=1.6，九年以前），膝內障礙（ICD-9:717，OR=1.9，五年以前），椎間盤疾患（ICD-9:722，OR=1.4，五年以前），頭臉頸部狀挫傷（ICD-9:920，OR=1.5，五年以前），神經根及神經叢疾患（ICD-9:353，OR=1.5，三年以前），營養、新陳代謝和發育的症狀（ICD-9:783，OR=2.1，三年以前），病毒性疫苗接種（ICD-9:V04，OR=1.4，一年以前），其他錐體外疾病及不正常動作疾病（ICD-9:333，OR=1.9，一年以前），上肢神經炎（ICD-9:354，OR=1.3，一年以前），下肢單一神經炎（ICD-9:355，OR=1.5，一年以前），末梢神經病變（ICD-9:356，OR=1.7，一年以前），發炎性及中毒性神經病變（ICD-9:357，OR=1.7，一年以前），腦動脈阻塞（ICD-9:434，OR=1.6，一年以前），氣喘（ICD-9:493，OR=1.3，一年以前），蜂窩性組織炎（ICD-9:682，OR=1.3，一年以前），脊椎關節病（ICD-9:721，OR=1.2，一年以前），肌肉、韌帶及筋膜疾患（ICD-9:728，OR=1.4，一年以前）與ALS呈顯著正相關。
    另外，與ALS呈顯著負相關的過去疾病有糖尿病（ICD-9:250，OR=0.7，五年以前），皮膚和皮下組織障礙（ICD-9:709，OR=0.7，五年以前），慢性缺血性心臟病（ICD-9:414，OR=0.8，三年以前），牙齒硬組織疾病（ICD-9:521，OR=0.8，三年以前），十二指腸潰瘍（ICD-9:532，OR=0.7，三年以前），癰及癤（ICD-9:680，OR=0.7，三年以前），下肢挫傷（ICD-9:924，OR=0.8，三年以前），追蹤檢查（ICD-9:V67，OR=0.7，一年以前），中耳炎（ICD-9:382，OR=0.6，一年以前），胃功能障礙（ICD-9:536，OR=0.8，一年以前），類風溼性關節炎（ICD-9:714，OR=0.7，一年以前）。
    路徑分析顯示與ALS有負相關的11個疾病可歸納為糖尿病及其相關併發症；與ALS有正相關的17個疾病可歸納為新陳代謝異常、神經發炎、頭部外傷、運動傷害、感染等。
    結論：
    通過這些結果，我們可以假設高代謝綜合症疾病是ALS的可能成因，其保護因子為代謝綜合症疾病。

    Importance:
    Although many studies over the last 20 years have discovered diseases that may increase or decrease the risk of amyotrophic lateral sclerosis (ALS), inconsistent and ambiguous results muddle the direction of these associations.
    Objective:
    We investigated prior diseases associated with ALS using a total population-based medical claims database.
    Design:
    This was a total population-based case–control study. The index date was set as the date of diagnosis of ALS.
    Setting:
    This study was conducted using the National Health Insurance Research Database (NHIRD) and Serious Disabling Diseases (SDD) database in Taiwan.
    Participants:
    We included 705 new ALS cases aged more than 15 years from January 1, 2007, to December 31, 2013, and 14,100 sex-, age-, residence-, and insurance premium-matched controls.
    Exposure:
    Prior diseases were stratified as being diagnosed 1, 3, 5, 7, and 9 years prior to the ALS diagnosis date. Diseases were identified using the first 3 digits of International Classification of Diseases, ninth revision (ICD-9).
    Main Outcome Measure:
    ALS was classified according to the ICD-9 (335.20) by SDD database from Department of Health and Welfare, Taiwan.
    Statistics analysis:
    Chi-squared or t-test was used to examine differences in demographic characteristics between new patients with ALS and controls.
    Prior diseases were first screened using conditional logistic regression model. The false discovery rate (FDR)-adjusted P value was then reported to avoid inflating false positives. A disease with FDR-adjusted P<0.10 was considered as a significantly associated disease. After the significant prior diseases were found using univariate analysis, multivariate analysis was performed using stepwise selection to evaluate the association between these diseases and the risk of ALS. We also used the path analysis to analyze the pathway between prior diseases and ALS. The effects of prior diseases on ALS were also estimated.
    Result:
    The mean (± standard deviation) age of patients with ALS was 56.65 ± 11.38 years. Of 705 patients with ALS, 400 were males and 305 were females (1.3:1). Only 50 ALS cases lived in rural areas. Nearly half of the ALS cases were under social welfare or supported by family members.
    In this study, 28 prior diseases were associated with ALS, including 17 positive and 11 negative associations. Diseases positively associated with ALS were the following: general medical examination (ICD-9: V70, OR=1.3, before 9 years), internal derangement of knee (ICD-9: 717, OR=1.9, before 5 years), intervertebral disc disorders (ICD-9: 722, OR=1.4, before 5 years), contusion of the face, scalp, and neck (ICD-9: 920, OR=1.5, before 5 years), nerve root and plexus disorders (ICD-9: 353, OR=1.5, before 3 years), symptoms concerning nutrition, metabolism, and development (ICD-9: 783, OR=2.1, before 3 years), need for prophylactic vaccination and inoculation against certain diseases (ICD-9: V04, OR=1.4, before 1 year), other extrapyramidal disease and abnormal movement disorders (ICD-9:333, OR=1.9, before 1 years), mononeuritis of the upper limb and mononeuritis multiplex (ICD-9: 354, OR=1.3, before 1 year), mononeuritis of the lower limb (ICD-9: 355, OR=1.5, before 1 year), hereditary and idiopathic peripheral neuropathy (ICD-9: 356, OR=1.7, before 1 year), inflammatory and toxic neuropathy (ICD-9: 357, OR=1.7, before 1 year), occlusion of cerebral arteries (ICD-9: 434, OR=1.6, before 1 year), asthma (ICD-9: 493, OR=1.3 before 1 year), other cellulitis and abscess (ICD-9: 682, OR=1.3, before 1 year), spondylosis and allied disorders (ICD-9:721, OR=1.2, before 1 year), and disorders of the muscle, ligament, and fascia (ICD-9:728, OR=1.4, before 1 year.
    Diseases negatively associated with ALS were as follows: diabetes mellitus (ICD-9:250, OR=0.7 , before 5 years), other disorders of the skin and subcutaneous tissue (ICD-9:709, OR=0.7 , before 5 years), other forms of chronic ischemic heart disease (ICD-9:414, OR=0.8 , before 3 years), diseases of the hard tissues of the teeth (ICD-9:521, OR=0.8 , before 3 years), duodenal ulcer (ICD-9:532, OR=0.7 , before 3 years), carbuncle and furuncle (ICD-9:680, OR=0.7 , before 3 years), contusion of the lower limb (ICD-9:924, OR=0.8 , before 3 years), follow-up examination (ICD-9:V67, OR=0.7 , before 1 year), otitis media (ICD-9:382, OR=0.6 , before 1 year), disorders of function of the stomach (ICD-9:536, OR=0.8 , before 1 year), rheumatoid arthritis and other inflammatory polyarthropathies (ICD-9:714, OR=0.7 , before 1 year).
    Moreover, path analysis showed that the 11 negative association diseases can be considered as diabetes mellitus and its comorbidities. The 17 positive association diseases can be considered as metabolic syndrome, neuroinflammation, head trauma, sports injuries, infections, and their comorbidities.
    Conclusion:
    Our results supported the hypothesis that prior diseases for ALS were hypermetabolic syndrome diseases. Moreover, the hypometabolic syndrome diseases may have a beneficial effect on ALS incidence.

    Contents Abstract 1 中文摘要 5 Chapter 1 Introduction 8 1.1 Research background 8 1.2 Study objective 9 Chapter 2 Literature Review 10 2.1 Introduction to amyotrophic lateral sclerosis (ALS) 10 2.2 Epidemiology and pathology of ALS population 12 2.2.1 Neoplasm (ICD-9: 140–239) 13 2.2.2 Disorders of the thyroid gland (ICD-9:240–246) 14 2.2.3 Diabetes mellitus (ICD-9:250) 14 2.2.4 Overweightness, obesity, and other hyperalimentation disorders (ICD-9:278) and disorders of lipid metabolism (ICD-9:272) 15 2.2.5 Mental disorders (ICD-9:290–319) 15 2.2.6 Diseases of the nervous system and sense organs (ICD-9:320–389) 16 2.2.7 Diseases of the circulatory system (ICD-9:390–459) 16 2.2.8 Diseases of the respiratory system (ICD-9:460–519) 17 2.2.9 Other diseases of the digestive system and liver (ICD-9:570–573) 18 2.2.10 Arthropathies and related disorders (ICD-9:710–739) 18 2.2.11 Head trauma 18 (open wound of head (ICD-9:873) and contusion of eye and adnexa (ICD-9:921)) 18 2.2.12 PA 18 Chapter 3 Material and Methods 24 3.1 Ethics statement 24 3.2 Data sources 24 3.3 Study Design and Population 25 3.4 Statistical analysis 28 Chapter 4 Results 31 4.1 Sample characteristics 31 4.2 Prior diseases associated with ALS incidence: Univariate analysis 33 4.2.1 Hereditary and degenerative diseases of the central nervous system (ICD-9: 330–337) 33 4.2.2 Disorders of the peripheral nervous system (ICD-9: 350–359) 34 4.2.3 Diseases of oral cavity, salivary glands, and jaws (ICD-9: 520–529) 35 4.2.4 Diseases of the musculoskeletal system and connective tissue (ICD-9:710–739) 35 4.2.5 Other diseases associated with ALS incidence 37 4.3 Diseases associated with ALS incidence: Multivariate analysis 42 4.3.1 Disorders of the peripheral nervous system (ICD-9: 350–359) 42 4.3.2 Diseases of the ear and mastoid process (ICD-9: 380–389) 42 4.3.3 Diseases of the circulatory system (ICD-9: 390–459) 43 4.3.4 Diseases of the respiratory system (ICD-9: 460–519) 43 4.3.5 Diseases of the oral cavity, salivary glands, and jaws (ICD-9: 520–529) 43 4.3.6 Diseases of the esophagus, stomach, and duodenum (ICD-9: 530–538) 44 4.3.7 Diseases of the skin and subcutaneous tissue (ICD-9: 680–709) 44 4.3.8 Diseases of the musculoskeletal system and connective tissue (ICD-9: 710–739) 44 4.3.9 Injury (ICD-9: 800-999) 45 4.3.10 Other diseases associated with ALS incidence 45 4.4 Prior diseases associated with ALS incidence: Path analysis 50 4.4.1 Prior diseases associated with ALS incidence, determined using path analysis 50 4.4.2 Positive associations 51 4.4.3 Negative associations 54 4.4.4 Combination of positive and negative associations into one model 57 Chapter 5 Discussion and Conclusion 61 5.1 Hypometabolism as a potential protective factor for ALS 61 5.2 Hypermetabolism as a potential risk factor for ALS 63 5.3 Strengths of this study 66 5.4 Conclusion 66 Chapter 6 Limitations 76 Reference 78 Appendix I 84

    1.Radunovic A, Annane D, Rafiq MK, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Library. 2013.
    2.Tsai C-P, Lin F-C, Lee JK-W, Lee CT-C. Aspirin Use Associated With Amyotrophic Lateral Sclerosis: a Total Population-Based Case-Control Study. Journal of Epidemiology. 2015;25(2):172.
    3.Tsai C-P, Wang K-C, Hwang C-S, Lee I-T, Lee CT-C. Incidence, prevalence, and medical expenditures of classical amyotrophic lateral sclerosis in Taiwan, 1999–2008. Journal of the Formosan Medical Association. 2015;114(7):612-619.
    4.Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study. JAMA neurology. 2015;72(8):905-911.
    5.Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. European Journal of Neurology. 2015;22(11):1436-1442.
    6.Sun Y, Lu C-J, Chen R-C, Hou W-H, Li C-Y. Risk of Amyotrophic Lateral Sclerosis in Patients With Diabetes: A Nationwide Population-Based Cohort Study. Journal of epidemiology/Japan Epidemiological Association. 2014;25(6):445-451.
    7.Ji J, Sundquist J, Sundquist K. Association of alcohol use disorders with amyotrophic lateral sclerosis: a Swedish national cohort study. Eur J Neurol. 2016;23(2):270-275.
    8.Turner M, Goldacre R, Talbot K, Goldacre M. Psychiatric disorders prior to amyotrophic lateral sclerosis. Annals of neurology. 2016.
    9.Sutedja NA, van der Schouw YT, Fischer K, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(6):638-642.
    10.Hardiman O. Amyotrophic lateral sclerosis and vascular risk: a metabolic conundrum. J Neurol Neurosurg Psychiatry. 2011;82(6):591.
    11.Turner MR, Goldacre R, Talbot K, Goldacre MJ. Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 2015;87(3):244-246.
    12.Logroscino G, Ludolph A. Amyotrophic lateral sclerosis: new ideas from cancer. Lancet Neurol. 2014;13(11):1067-1068.
    13.Gibson SB, Abbott D, Farnham JM, et al. Population-based risks for cancer in patients with ALS. Neurology. 2016;87(3):289-294.
    14.Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis An epidemiologic study. Neurology. 2013;81(14):1222-1225.
    15.Paganoni S, Hyman T, Shui A, et al. Pre‐morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle & nerve. 2015;52(3):339-343.
    16.Sun Y, Lu CJ, Chen RC, Hou WH, Li CY. Risk of Amyotrophic Lateral Sclerosis in Patients With Diabetes: A Nationwide Population-Based Cohort Study. J Epidemiol. 2015;25(6):445-451.
    17.Freedman DM, Wu J, Daugherty SE, Kuncl RW, Enewold LR, Pfeiffer RM. The risk of amyotrophic lateral sclerosis after cancer in U.S. elderly adults: a population-based prospective study. International journal of cancer. 2014;135(7):1745-1750.
    18.Ascherio A, O’Reilly EJ. New insights on physical activity and amyotrophic lateral sclerosis. European Journal of Epidemiology. 2016;31(3):213-215.
    19.Fang F, Hållmarker U, James S, et al. Amyotrophic lateral sclerosis among cross-country skiers in Sweden. European Journal of Epidemiology. 2016;31(3):247-253.
    20.Harwood CA, Westgate K, Gunstone S, et al. Long-term physical activity: an exogenous risk factor for sporadic amyotrophic lateral sclerosis? Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2016:1-8.
    21.Lacorte E, Ferrigno L, Leoncini E, Corbo M, Boccia S, Vanacore N. Physical activity, and physical activity related to sports, leisure and occupational activity as risk factors for ALS: A systematic review. Neuroscience & Biobehavioral Reviews. 2016;66:61-79.
    22.Seals RM, Hansen J, Gredal O, Weisskopf MG. Physical Trauma and Amyotrophic Lateral Sclerosis: A Population-Based Study Using Danish National Registries. American journal of epidemiology. 2016;183(4):294-301.
    23.Duffy L, Chapman A, Shaw P, Grierson A. Review: the role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis. Neuropathology and applied neurobiology. 2011;37(4):336-352.
    24.Chio A, Logroscino G, Traynor B, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118-130.
    25.Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. The Lancet. 2011;377(9769):942-955.
    26.Shahrizaila N, Sobue G, Kuwabara S, et al. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. Journal of neurology, neurosurgery, and psychiatry. 2016;87(8):821-830.
    27.Pupillo E, Messina P, Logroscino G, Beghi E, Group S. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Annals of neurology. 2014;75(2):287-297.
    28.Staff NP. Variability in Amyotrophic Lateral Sclerosis. JAMA Neurology. 2016;73(7):781-782.
    29.Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handbook Of Clinical Neurology. 2016;138:225-238.
    30. Juneja T, Pericak-Vance MA, Laing NG, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis progression and survival in patients with Glu100gly and Ala4val mutations in Cu, Zn superoxide dismutase. Neurology. 1997;48(1):55-57.
    31.Klein CJ, Wu Y, Duan X, et al. Novel SOD1 mutation discovered in atypical ALS by whole exome sequencing. Journal of Neurology, Neurosurgery & Psychiatry. 2013;84(8):943.
    32.Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain. 2012;135(3):765-783.
    33.Paganoni S, Macklin EA, Lee A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2014;15(5-6):453-456.
    34.Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Journal of the neurological sciences. 1994;124:96-107.
    35.Shook SJ, Pioro EP. Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient. Annals of neurology. 2009;65(S1).
    36.Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nature Reviews Neurology. 2013;9(11):617-628.
    37.Mehta P. Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, Atlanta, Georgia; Centers for Disease Control and Prevention (CDC). Prevalence of amyotrophic lateral sclerosis—United States, 2010–2011. MMWR Surveillance summaries. 2014;63:1.
    38.Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. Journal of Neurology, Neurosurgery & Psychiatry. 2010;81(4):385-390.
    39.Tsai C-P, Wang K-C, Hwang C-S, Lee IT, Lee C. Incidence, prevalence, and medical expenditures of classical amyotrophic lateral sclerosis in Taiwan, 1999–2008. Journal of the Formosan Medical Association. 2015;114(7):612-619.
    40.Freedman DM, Curtis RE, Daugherty SE, Goedert JJ, Kuncl RW, Tucker MA. The association between cancer and amyotrophic lateral sclerosis. Cancer Causes & Control. 2013;24(1):55-60.
    41.Seelen M, van Doormaal PT, Visser AE, et al. Prior medical conditions and the risk of amyotrophic lateral sclerosis. Journal of neurology. 2014;261(10):1949-1956.
    42.Hollinger SK, Okosun IS, Mitchell CS. Antecedent Disease and Amyotrophic Lateral Sclerosis: What Is Protecting Whom? Front Neurol. 2016;7:47.
    43.Turner MR, Wotton C, Talbot K, Goldacre MJ. Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study. J Neurol Neurosurg Psychiatry. 2012;83(4):395-398.
    44.Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. Journal of Neurology, Neurosurgery & Psychiatry. 2012;83(1):102-108.
    45.Kioumourtzoglou M-A, Seals RM, Gredal O, Mittleman MA, Hansen J, Weisskopf MG. Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: A population based study. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2016;17(7-8):548-554.
    46.Visser AE, Seelen M, Hulsbergen A, et al. Exploring the fitness hypothesis in ALS: a population-based case-control study of parental cause of death and lifespan. Journal of Neurology, Neurosurgery & Psychiatry. 2017.
    47.Mitchell CS, Hollinger SK, Goswami SD, Polak MA, Lee RH, Glass JD. Antecedent Disease is Less Prevalent in Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases. 2015;15(2):109-113.
    48.Elisabetta Pupillo, Marco Poloni, Elisa Bianchi, et al. Trauma and Amyotrophic Lateral Sclerosis: A European population-based case-control study from the EURALS Consortium. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2016.
    49.Longinetti E, Mariosa D, Larsson H, et al. Physical and cognitive fitness in young adulthood and risk of amyotrophic lateral sclerosis at an early age. European Journal of Neurology. 2017;24(1):137-142.
    50.Fang F, Al-Chalabi A, Ronnevi LO, et al. Amyotrophic lateral sclerosis and cancer: a register-based study in Sweden. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(5-6):362-368.
    51.Timmins HC, Saw W, Cheah BC, et al. Cardiometabolic Health and Risk of Amyotrophic Lateral Sclerosis. Muscle & Nerve. 2016:n/a-n/a.
    52.Fondell E, Fitzgerald KC, Falcone GJ, O'Reilly ÉJ, Ascherio A. Early-onset alopecia and amyotrophic lateral sclerosis: a cohort study. American journal of epidemiology. 2013;178(7):1146-1149.
    53.Institutes NHR. National Health Insurance Research Database. In. Taiwan.
    54.Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behavioural brain research. 2001;125(1):279-284.
    55.Bagozzi RP, Yi Y. On the evaluation of structural equation models. Journal of the academy of marketing science. 1988;16(1):74-94.
    56.Chieh-Yu Liu Y-TH, Yi-Li Chuang, Yi-Ju Chen, Wen-Shun Weng, Jih-Shin Liu, Kung-Yee Liang. Incorporating Development Stratification of Taiwan Townships into Sampling Design of Large Scale Health Interview Survey. Journal of Health Management. 2006;4(1):1-22.
    57.Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. The Lancet Neurology. 2013;12(3):310-322.
    58.Jaramillo A, Contreras A, Lafaurie GI, et al. Association of metabolic syndrome and chronic periodontitis in Colombians. Clinical Oral Investigations. 2017;21(5):1537-1544.
    59.Kikui M, Kokubo Y, Ono T, et al. Relationship between Metabolic Syndrome Components and Periodontal Disease in a Japanese General Population: the Suita Study. Journal of Atherosclerosis and Thrombosis. 2017;24(5):495-507.
    60.Kaye EK, Chen N, Cabral HJ, Vokonas P, Garcia RI. Metabolic Syndrome and Periodontal Disease Progression in Men. Journal of Dental Research. 2016;95(7):822-828.
    61.Morita T, Yamazaki Y, Mita A, et al. A cohort study on the association between periodontal disease and the development of metabolic syndrome. Journal of periodontology. 2010;81(4):512-519.
    62.D'Aiuto F, Sabbah W, Netuveli G, et al. Association of the metabolic syndrome with severe periodontitis in a large US population-based survey. The Journal of Clinical Endocrinology & Metabolism. 2008;93(10):3989-3994.
    63.Khader Y, Khassawneh B, Obeidat B, et al. Periodontal status of patients with metabolic syndrome compared to those without metabolic syndrome. Journal of periodontology. 2008;79(11):2048-2053.
    64.Morita T, Ogawa Y, Takada K, et al. Association between periodontal disease and metabolic syndrome. Journal of public health dentistry. 2009;69(4):248-253.
    65.Kaya S, Selimoğlu E, Cureoğlu S, Selimoğlu M. Relationship between chronic otitis media with effusion and overweight or obesity in children. The Journal of Laryngology & Otology. 2017:1-5.
    66.Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. Journal of Clinical Investigation. 2004;113(3):321.
    67.Furuta T, Shirai N, Xiao F, Takashima M, Hanai H. Effect of Helicobacter pylori infection and its eradication on nutrition. Alimentary pharmacology & therapeutics. 2002;16(4):799-806.
    68.Tatsuguchi A, Miyake K, Gudis K, et al. Effect ofHelicobacter pyloriInfection on Ghrelin Expression in Human Gastric Mucosa. American Journal of Gastroenterology. 2004;99(11):2121-2127.
    69.Galvin M, Ryan P, Maguire S, et al. The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: A population-based study of consultations, interventions and costs. PloS one. 2017;12(6):e0179796.
    70.Belsh JM, Schiffman PL. The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions. Journal of the neurological sciences. 1996;139:110-116.
    71.Wokke JH. Confounding effects of mimicking disorders in the early diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2000;1(sup1):S61-S63.
    72.Cellura E, Spataro R, Taiello AC, La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clinical neurology and neurosurgery. 2012;114(6):550-554.
    73.The ETFoD, Management of Amyotrophic Lateral S, Andersen PM, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force. European Journal of Neurology. 2012;19(3):360-375.
    74.Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nature Reviews Neurology. 2011;7:639.
    75.Chiò A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain. 2005;128(3):472-476.
    76.Bar-Sela S, Reingold S, Richter ED. Amyotrophic Lateral Sclerosis in a Battery-factory Worker Exposed to Cadmium. International Journal of Occupational and Environmental Health. 2001;7(2):109-112.
    77.O'Reilly ÉJ, Wang H, Weisskopf MG, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2013;14(3):205-211.
    78.Mandrioli J, Faglioni P, Merelli E, Sola P. The epidemiology of ALS in Modena, Italy. Neurology. 2003;60(4):683-689.
    79.Govoni V, Granieri E, Fallica E, Casetta I. Amyotrophic lateral sclerosis, rural environment and agricultural work in the Local Health District of Ferrara, Italy, in the years 1964–1998. Journal of neurology. 2005;252(11):1322.
    80.Gallo V, Wark PA, Jenab M, et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis the EPIC cohort. Neurology. 2013;80(9):829-838.
    81.Smit J, Søgaard M, Schønheyder HC, Nielsen H, Frøslev T, Thomsen RW. Diabetes and risk of community-acquired Staphylococcus aureus bacteremia: a population-based case–control study. European journal of endocrinology. 2016;174(5):631-639.
    82.Aliyu I, Kumurya A, Bala J, John O. Bacteriology of Otitis Media and Its Host-Environmental-Infection Factors. Asia Pacific Environmental and Occupational Health Journal. 2017;3(1).
    83.Bettenworth D, Nowacki TM, Friedrich A, Becker K, Wessling J, Heidemann J. Crohn’s disease complicated by intestinal infection with methicillin-resistant Staphylococcus aureus. World Journal of Gastroenterology : WJG. 2013;19(27):4418-4421.
    84.Ibler KS, Kromann CB. Recurrent furunculosis – challenges and management: a review. Clinical, Cosmetic and Investigational Dermatology. 2014;7:59-64.

    下載圖示
    QR CODE